How to Control Impurities during API drug manufacturing

Posted: February 19, 2018

API Manufacturing and Pharmaceutical Manufacturing

Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.

Related posts:

API Purification Methods: Do You Know How To Pick the Best One?
PCI Synthesis at DCAT Week 2017
How to Select a CMO
Is Your CMO Qualified to Handle Your API Project?
Top Early Stage Method Validation Mistakes and How to Avoid Them

About the Author

Ed Price CEO of PCI Synthesis
Ed is the President and CEO of PCI Synthesis (PCI), he serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA).

Do you have questions? Talk to Ed.